KRYS — Krystal Biotech Inc

Krystal Biotech Inc (KRYS) is a biotechnology company listed on NASDAQ. It is led by Krish S. Krishnan M.B.A., M.S., based in 2100 Wharton Street, Pittsburgh, PA, United States, 15203, with about 295 employees. Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Latest reported KRYS revenue for 2025-09-30 was $97.8M. Net income was $79.4M. Revenue was up 1.8% from 2025-06-30 to 2025-09-30. KRYS currently screens at market cap $10.17B and trailing P/E 46.1.

Use this KRYS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the KRYS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the KRYS SEC filings page. Lician reads the product cache first so this HTML stays unique to Krystal Biotech Inc even when a live quote feed is slow.